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1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. 
Disease flares can occur at any time during pregnancy and postpartum without any clear 
pattern. 
The hormonal and physiological changes that occur in pregnancy can induce lupus activity. 
Likewise the increased inflammatory response during a lupus flare can cause significant 
complications in pregnancy. Distinguishing between signs of lupus activity and pregnancy 
either physiological or pathological can be difficult [Clowse, 2007]. 
Pregnancy is a crucial issue that needs to be clearly discussed in details in all female patients 
with SLE who are in the reproductive age group. There are two essential concerns. The first 
one is the Lupus activity on pregnancy and the second one is the influence of pregnancy on 
Lupus. That is the reason why pregnancy should be planned at least six months of remission 
with close follow-up for SLE flares. 
Women with SLE usually have complicated pregnancies out of which one third will result in 
cesarean section, one third will have preterm delivery and more than 20% will be 
complicated by preeclampsia [Clowse, 2006; Clark, 2003]. Rarely an SLE patient with a 
controlled disease activity may deteriorate as pregnancy advances, but still the pregnancy 
outcome can be better if pregnancy is well timed and managed. 
2. Physiology of pregnancy 
There are increased demands by the mother, fetus and the placenta during pregnancy which 
is to be met by the mother’s organ systems. Therefore there are some cardiovascular, 
hematological, immunological, endocrinal and metabolic changes in the mother in normal 
pregnancy. 
2.1 Cardiovascular system 
The most important physiological changes that occur in pregnancy are the increase in 
cardiac output, retention of sodium and water leading to increase in the blood volume, 
reduction in systemic vascular resistance and blood pressure. These changes begin as early 
as fourth week of pregnancy [Chapman, 1998], reaching their peak during the second 
trimester, and then remain relatively constant until delivery. As the increase in the red cell 
volume is proportionately less than the increase in plasma volume there is hemodilution 
(physiological anemia) by the end of second trimester [Table 1]. The plasma volume gain is 
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between 1000ml to 1500ml while the blood volume at term is about 100ml/kg which could 
commonly present as mild pedal edema [Jansen, 2005] 
The increased levels of plasma erythropoietin is responsible for steady increase in the red 
cell mass by 20-30% who take iron supplements and by 15-20% in those who do not take 
iron supplements. The physiological anemia that occurs in pregnancy reduces the cardiac 
work load and helps for better placental perfusion by decreasing the blood viscosity.  
It also decreases the risk of thrombosis in utero-placental circulation. The increased blood 
volume also protects against the usual blood loss in the peripartum period [Stephansson, 
2000]. The hemoglobin begins to increase from the third postpartum day and the blood 
volume returns to non-pregnant level by two months postpartum.  
Cardiac output- It increases by 30-50% during normal pregnancy [Robson, 1989]. This is as a 
result of increase in the preload due to rise in blood volume, decrease in afterload due to 
decrease in systemic vascular resistance and increase in the maternal heart rate by 15-20 
beats/min without any change in the ejection fraction. Twin pregnancy increase the cardiac 
output by another 20%. However, maternal heart rate, stroke volume, and cardiac output 
during pregnancy may vary when mother changes from lateral to supine position 
[Lang,1991, Kametas,2003].  
Hemodynamic changes related to labor and delivery — Normal labor and delivery is 
associated with significant hemodynamic changes due to anxiety, exertion, labor pains, 
uterine contractions, uterine involution, and bleeding. Cardiovascular effects also occur in 
some women due to infection, hemorrhage, or the administration of anesthesia or analgesia. 
The cardiac output and systemic vascular resistance gradually return to non-pregnant levels 
over a period of three months [Capeless, 1991]. 
2.2 Hematological changes 
The total white cell count is increased up to 40% due to the increase in neutrophils as a 
result of demargination seen in pregnancy. Therefore the WBC count increases gradually in 
pregnancy as follows: 
1st trimester- 3000-15,000 (Mean increase 9500/mm3)    
2nd and 3rd trimesters- 6000-16,000 (mean 10,500)  
During labor-may increase up to 30,000/ mm3 
The platelet count gradually decreases till the term although they do not fall below 
100,000/cu mm, most of the time they are in the lower range of normal values. This is as a 
result of dilutional effect, increased destruction and turn over. 
The RBC increased by 20% due to increased production of erythropoietin but as the plasma 
volume is increased more than the red cell volume there is a drop in the hemoglobin causing 
physiological anemia [McColl, 1997]. 
2.3 Changes in systemic coagulation 
Pregnancy is associated with changes in several coagulation factors that result in a 20 
percent reduction of prothrombin and the partial thromboplastin times. The main changes 
are:  
 Increased Resistance to activated protein C in the second and third trimesters  
 Decreased levels of Protein S  
 Increased levels of Factors I, VII, VIII, IX, and X    
 Increased Activity of the fibrinolytic inhibitors PAI-1 and PAI-2, although total 
fibrinolytic activity may not be impaired       
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       PARAMETER  IN PREGNANCY 
                         
CHANGE (+/-) 
 
Stroke volume                   
Heart rate                         
Cardiac output                   
Oxygen consumption        
SVR (systemic vascular resistance)  
Systolic BP                        
Diastolic BP                      
Mean BP                         
 
+30% 
+15% 
+40% 
+20% 
-5% 
-10mmHg 
-15mmHg 
-15mmHg 
 
Blood volume                 
Plasma volume               
Red blood cell volume  
Renal plasma flow 
Glomerular filtration rate (GFR) 
Polymorphonuclear leukocytes      
Hemoglobin  (11 g%) 
Leucocytosis  (15,000/cmm) 
Platelet  (may drop upto 100,000) 
ESR (may go up to 40mm/Hr 
 
+30% 
+40% 
+20% 
+35% 
+50% 
+40% 
-1-2G% 
+40% 
Decreased 
Increased  
 
Fibrinogen (up to 4.5G %) 
Factor II,III,V,XII 
Factors I,VII,VIII,IX,X 
Factors XI,XIII 
PT & APTT 
Bleeding time & clotting time 
Fibrinolytic activity        
Complement C3, C4 levels                    
 
+50% 
No change 
Increased 
Decreased 
Reduced 
Unchanged  
Decreased  
+10-50% 
Table 1. Changes in maternal physiology in pregnancy 
(Christopher Ficiliberto & Gertic F.Marx.(1998). Physiological changes 
associated with pregnancy. Physiology, 9(2):1-3)  
The net effect of these pregnancy-induced changes is to produce a hypercoagulable state, 
which is a double-edged sword, both for protection (e.g., hemostasis contributing to 
reduced blood loss at delivery) and increased risk (e.g., thromboembolic phenomenon). 
Venous thrombosis in pregnancy occurs in approximately 0.7 per 1000 women, and is three 
to four folds higher in the puerpurium than during pregnancy. The risk is increased in 
women with underlying inherited thrombophilia (e.g. factor V Leiden or the prothrombin 
gene mutation) [Talbert, 1964; Hellgren, 1981]. 
2.4 Changes in the maternal immune system 
The local adaptation of the maternal immune system is responsible for the successful 
coexistence between the mother and the fetus/placenta expressing both maternal (self) and 
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paternal (non-self) genes [Mor, 2009; Robertson, 2010]. The cell- mediated adaptive immune 
responses are diminished, bypassed or even eliminated but the anti-body mediated 
immunity is altered while the natural immunity (innate immunity) remains intact which 
continues to provide the host defense against infection [Nagamatsu, 2010]. 
During insemination, transforming growth factor β1 (TGF- β1), found in the seminal fluid 
stimulates the production of granulocyte-macrophage colony- stimulation factor (GM-CSF) 
and recruitment of inflammatory cell infiltrates in the uterus. During implantation of the 
fertilized ovum, the majority of the lymphocytes infiltrating the decidua are distinctive uterine 
natural killer (NK) cells which are CD56++, CD16- & CD3- and express various receptors. 
Uterine decidua and the feto-placental unit produces large number of cytokines which 
contribute to shift of the immune response from T helper -1 (Th1) to T helper-2 (Th2) response 
where cytokines IL-10, IL-4, IL-5,IL-6 and IL-13 predominate while pregnancy rejection is 
mediated by Th1 response where IFN-ǂ, TNF-β, IL-2, and IL-12  predominate [Lim,2000]. 
There are many specific mechanisms for immunological protection against the fetus. The 
most important one is altered HLA expression. 
2.4.1 HLA class I 
Very specific expression of the HLA class I molecules in trophoblasts is the main factor for 
protection against paternal HLA class I antigen. The extra-villous trophoblasts (EVT) will not 
express the HLA class Ia antigens-A, B, C or HLA II antigens but instead they express weak 
antigens of HLA class Ib – G, E & F which dampen the immune response by interacting with 
leukocyte inhibitory receptor (LIRs) on uterine natural killer (NK) cells and macrophages and 
with the T-cell receptors on CD8+ cells [Tilburgs, 2010; Le, 1997; Hunt, 2006). 
2.4.2 Natural killer cells 
There is a change in the relative population of lymphocytes in the uterus. The T & B cells 
become scarce and the uterine natural killer (NK) cell population shifts from endometrial 
NK cells to decidual NK cells. 
2.4.3 Progesterone 
The role of progesterone, the hormone of pregnancy, seems to be crucial in the maintenance 
of pregnancy.  Progesterone leads to release of progesterone-induced blocking factor (PIBF), 
which controls cytokine production (IL-10 & others) and NK cell behavior. Increased 
embryo loss is associated with decreased levels of PIBF & IL-10 and increased levels of IL-12 
and IFN-α [Ito, 1995; Nilsson, 1994]. 
2.5 Hormonal changes in pregnancy  
Maternal changes in pregnancy involve hypothalamus, pituitary, parathyroid, adrenal 
glands, and ovaries to accommodate the needs of the fetal-placental-maternal unit. The 
hypothalamus still regulates much of the endocrine system through hypothalamic-pituitary 
axis, directly affecting the function of the above mentioned endocrine organs. Hence an 
intact hypothalamus is very much essential for normal pregnancy [Chrousos, 1995]. 
2.5.1 Hypothalamus 
Secretes stimulatory hormones like gonadotropin-releasing hormone (GnRH), 
corticotrophin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), 
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thyrotropin-releasing hormone (TRH) and inhibitory hormones like somatostatin and 
prolactin-inhibiting factors. These hormones are present in high concentrations in portal 
circulation where they are biologically active and the circulating concentrations of many of 
these hormones are also elevated in pregnancy due to placental production of identical or 
variant hormones. The most important changes are seen in the following hormones 
[Stojilkovic, 1994]. 
GnRH levels increases during pregnancy whose main source is placenta and plays a main 
role in placental growth and function. It also produces kisspeptin (KISS-1) which controls 
the gonadotropic axis and placental kisspeptin gradually increases with pregnancy which 
has a role in placentation [Bilban, 2004]. 
CRH from hypothalamus is involved in stress response in pregnancy and delivery. It is also 
secreted by placenta, chorionic trophoblasts, amnion and decidual cells. The placental CRH 
do not stimulate ACTH secretion but helps in initiation of labor. Besides CRH the 
gestational tissues also secretes urocortin which shares the same function of placental CRH, 
and urocortin-2 (stresscopin- related peptide) and urocortin-3 (stresscopin) which controls 
the tone of vascular endothelium also play a major role in parturition [Imperatore,2006; 
Florio, 2007]. 
2.5.2 Pituitary gland 
Changes occur both in the anterior as well as the posterior lobe of pituitary gland. 
Anterior lobe of pituitary gland enlarges to 3-fold during gestation due to hypertrophy and 
hyperplasia of lactotrophs and it takes at least six months after delivery to return to normal 
volume. FSH, LH & TSH levels are decreased while GH, ACTH & PRL levels are increased 
(mainly due to placental synthesis) [Lonberg, 2003]. 
The serum prolactin concentration (PRL) increases throughout pregnancy, reaching a peak 
at delivery to prepare the breast for lactation (figure 1) [Tyson, 1972], though the magnitude 
of the increase is quite variable. 
 
 
Fig. 1. Serum prolactin concentrations, as a function of time of gestation, showing the 
increase in prolactin as pregnancy progresses. The zone lines represent the range of values 
that can be seen. (Tyson, 1972) 
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The probable cause of hyperprolactinemia is the increasing serum estradiol concentration 
during pregnancy. By six weeks after delivery, estradiol secretion decreases and the basal 
serum prolactin concentration returns to normal range as in non-breast feeding mother. In 
women who are nursing, the decline in serum prolactin level is slower and marked by 
intermittent hyperprolactinemia related to suckling. Pregnancy appears to permanently 
reduce pituitary prolactin secretion. The serum prolactin concentration was lower in parous 
women at up to 12 years postpartum [Musey, 1987]. 
Posterior lobe of pituitary gland is a storage terminal for antidiuretic hormone (ADH) and 
oxytocin produced by supraoptic and paraventricular hypothalamic nuclei. 
ADH- Its concentration remains in the non-pregnant range throughout pregnancy. Its 
metabolic clearance is increased due to vasopressinase released by placenta. The plasma 
sodium concentration falls by 5 meq/ L due to resetting of osmoreceptors as a result of 
increased levels of HCG. 
Oxytocin- Its levels increases gradually throughout gestation and is involved in parturition 
and lactation [Lindheimer, 1991]. 
2.5.3 Thyroid gland 
The size of the thyroid gland remains the same throughout the pregnancy but there is 
increase in the thyroxin-binding globulin (TBG). This leads to increased levels of both serum 
total thyroxin (T4) and triiodothyroxin (T3) but not the physiologically important serum free 
T4 & free T3 levels [Glinoer, 1990]. 
2.5.4 Adrenal gland 
This gland does not undergo morphological changes during pregnancy. The renin-
angiotensin-aldesterone system is stimulated during pregnancy due to decrease in 
peripheral vascular resistance and blood pressure and progressive decline in vascular 
responsiveness to angiotensin II. The aldesterone levels increased by 4-6 folds and the blood 
pressure usually reduced by 10mmHg. Relaxin, which is produced by the placenta, is  
a vasodilator factor, and aldesterone are critical in maintaining sodium balance in the setting 
of peripheral vasodilatation. During pregnancy there is increase in the levels of maternal  
& placental ACTH, cortisol-binding protein, atrial natriuretic peptide (ANP), plasma  
rennin activity (PRA), sex hormone-binding protein and testosterone levels [Homsen, 1993; 
Clerico, 1980]. 
2.6 Changes in the renal system in pregnancy  
Both kidneys increase in size by 1 to 1.5 cm during pregnancy. Kidney volume increases 
by 30 percent, primarily due to an increase in renal vascular and interstitial volume. The 
renal pelvises and caliceal systems may be dilated as a result of progesterone effects and 
mechanical compression of the ureters at the pelvic brim. Dilatation of the ureters and 
renal pelvis (hydroureter and hydronephrosis) is more prominent on the right than the 
left and is seen in up to 80 percent of pregnant women [Beydoun, 1985]. All the above 
changes may not resolve until 6 to 12 weeks postpartum. Urinary frequency, nocturia, 
dysuria, urgency, and stress incontinence are the common symptoms during pregnancy 
[Nel, 2001]. 
Renal hemodynamics — Normal pregnancy is characterized by widespread vasodilatation 
with increased arterial compliance and decreased systemic vascular resistance. These global 
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hemodynamic changes are accompanied by increases in renal perfusion and glomerular 
filtration rate. In late gestation, assumption of the left lateral position is associated with 
increases in glomerular filtration rate and sodium excretion [Almeida, 2009]. The increase in 
GFR which is approximately 40-50% is mainly due to increased glomerular plasma flow 
than increased intraglomerular capillary pressure. The renal blood flow increases by 80% 
above non-pregnant levels. As a result, the serum creatinine and BUN falls below the non-
pregnant levels. 
The mechanisms for decreased vascular resistance and increased renal plasma flow during 
pregnancy are not fully understood. Reduced vascular responsiveness to vasopressors such 
as angiotensin II, norepinephrine, and vasopressin is well-documented. Nitric oxide 
synthesis increases during normal pregnancy and may contribute to the systemic and renal 
vasodilatation and the fall in blood pressure [Danielson’, 1995]. 
The ovarian vasodilator hormone, relaxin,  appears to be a key upstream mediator of 
enhanced nitric oxide signaling in pregnancy. Relaxin increases endothelin and nitric oxide 
production in the renal circulation, leading to generalized renal vasodilatation, decreased 
renal afferent and efferent arteriolar resistance, and a subsequent increase in renal blood 
flow and GFR.  There is increased urinary protein excretion up to 200 mg/day in the third 
trimester [Novak, 2001]. 
3. Distinguishing lupus activity from signs and symptoms of pregnancy 
Systemic lupus erythematosus (SLE) primarily affects women in their reproductive years of 
life, making the issue of pregnancy important to many of these patients. Pregnancy changes 
affecting disease severity can be attributed to placental or maternal hormones, increased 
circulation, increased fluid volume, increased metabolic rate, hemodilution, circulating fetal 
cells, or other factors. Lupus flares are common in pregnancy at rate of 0.06-0.136 per 
patient-month [Table 2]. 
Likewise, the increased inflammatory response during a lupus flare can cause significant 
pregnancy complications. Distinguishing lupus activity from signs of both healthy and 
pathologic pregnancy is not straight forward and can be very difficult at times [Table 4]. 
Therefore, activity scales specific for pregnancy which takes into account these issues, have 
been established. One of them, the Lupus Activity Index in Pregnancy is actually validated, 
showing high sensitivity, specificity and predictive values for detecting flares during 
pregnancy [Clowse, 2006]. 
There is an increase in disease activity during pregnancy, according to many studies.  
In some patients, this will mean a dramatic worsening of symptoms that can be  
life threatening. Most patients, however, will have a modest increase in symptoms 
making pregnancy uncomfortable but not affecting their long-term survival. The 
increasing levels of estrogens that are seen in normal pregnancy to promote physiologic 
and immunologic changes required may also increase the lupus activity [Cohen-Solal, 
2006; Grimaldi, 2006]. Even though it is highly debated, at least some studies have found a 
two- to threefold increase in SLE activity during pregnancy [Petri, 1997; Lim, 1995; II 
Dong, 2011].  
40-50% of the patients will have increased SLE activity, majority of which are mild but in 
1/3 of cases it may be moderate to severe [Cortes-Hernandez., 2002]. Fortunately, the 
majority of SLE activity in pregnancy is not severe and in most studies, it is the skin, joint, 
and constitutional symptoms that are commonly seen. The physiological changes that occur 
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in pregnancy interfere with assessment of disease activity in SLE. So the signs and 
symptoms of pregnancy can easily be mistaken for increased lupus activity. 
Fatigue can be a distressing complaint throughout normal pregnancy. The fatigue of 
fibromyalgias increases during pregnancy. As there is no inflammation in this condition the 
excess sex hormones as well as steroids do not relieve pain. 
Palmar erythema and facial blush are also seen in pregnancy due to increased secretion of 
estrogens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Impact of pregnancy on lupus activity (adopted from Megan, 2007) 
Arthralgias, joint effusions, headaches and low back pain are also common in pregnancy 
due to the effects of relaxin, increased levels of estrogens and fluid retention. The increased 
shortness of breath is due to elevation of diaphragm as a result of upward growth of gravid 
uterus. The hair loss particularly during puerpurium and post-partum is a common finding 
in normal pregnancy.  
The HAQ (Health assessment questionnaire) score increases for normal pregnant women 
from 0.02 in the first trimester to 0.16 in the second and 0.48 in the third trimester.  
As the blood volume increases in pregnancy by 50% there is an effect of hemodilution in the 
body which decreases hemoglobin and platelets, however the hemolytic anemia and 
platelets less than 100,000/c mm do not occur in normal pregnancy, if present suspect either 
lupus activity, severe preeclampsia or HELLP (Hemolysis, Elevated Liver enzymes, Low 
Platelets) [Buyon, 1999].  
The risk for skin disease during pregnancy is higher (25-90%) than arthritis (20%), 
thrombocytopenia (10-40%) or nephritis (4-30%). Women with previous history of lupus 
nephritis have a higher chance for relapse of nephritits (20-30%). 
Due to increased blood volume and glomerular filtration rate the serum creatinine falls 
gradually and proteinuria increases during normal pregnancy. Therefore a stable serum 
creatinine that is maintained during pregnancy without a fall suggests renal insufficiency. 
Only proteinuria which is more than double the baseline is to be taken as abnormal, as 
proteinuria up to 300mg/24 hours can occur in normal pregnancy. A serum creatinine level 
                          Impact of pregnancy on SLE activity 
	
 Pregnancy probably increases lupus activity: 
 About 50% of women will have measurable SLE activity during pregnancy 
 Most of the disease activity will be mild to moderate 
 15% to 30% of women will have highly active SLE in pregnancy 
 Most common types of SLE activity in pregnancy: 
1. Cutaneous disease (25-90%) 
2. Arthritis (20%) 
3. Hematologic disease (10-40%) 
 
 Risk factors for increased lupus activity: 
1. Active lupus within the 6 months before conception 
2. Multiple flares in the years before conception 3. Discontinuation of hydroxychloroquin	
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>140 µmol/L is associated with a 50% pregnancy loss and this increases to 80% if the level is 
>400 µ mol/L [Megan, 2007]. 
 
Symptoms of pregnancy that can mimic lupus activity 
Constitutional Fatigue that can be debilitating in entire pregnancy. 
Skin Palmar erythema and a facial blush due to increased estrogen. 
Face 
 
Melasma: ‘‘mask of pregnancy.’’ A macular, photosensitive 
Hyperpigmented area over cheeks and forehead. 
Hair 
 
Increased hair growth and thickness during pregnancy. 
Hair loss in the weeks to months postpartum. 
Pulmonary     Increased respiratory rate from progesterone. 
Dyspnea from enlarging uterus late in pregnancy. 
Musculoskeletal 
 
 
 
Back pain in second and third trimesters. 
  -Relaxin loosens sacroiliac joint and symphysis pubis 
  -Gravid uterus increases lumbar lordosis. 
Joint effusions: non-inflammatory in lower extremities. 
Central nervous 
system 
 
 
 
Headache can be part of normal pregnancy 
or associated with hypertension. 
Seizures occur in eclampsia. 
Cerebral vascular accidents can be caused by preeclampsia or 
antiphospholipid syndrome. 
Table 3. Symptoms in pregnancy that mimics lupus activity 
(Adopted from Tsokos GC et al. Systemic lupus erythematosus, A companion to 
rheumatology. St. Louis: Mosby; 2007)  
Complement C3, C4, anti-dsDNA titer, autoimmune target testing (AITT) and  
lupus activity  
The activity of the lupus cannot accurately be assessed by the C3/C4 level and anti-dsDNA 
titers as in non-pregnant lupus patients. C3 and C4 may be decreased with increased lupus 
activity because these proteins are consumed in the inflammatory process [Ho A, 2001]. In 
pregnancy, however, the complement levels may increase 10-50% in response to increased 
hepatic protein synthesis [Buyon, 1992].  
During pregnancy, C3 and C4 may rise to supranormal levels, and thus a flare with 
complement activation may occur despite apparently normal levels of C3 and C4. 
Conversely C3and C4 may be low in the absence of a flare, probably due to synthetic 
defects. However, if C3 or C4 levels drop by >25%, this may be reasonably ascribed to 
disease activity [Buyon, 1999]. Therefore, the utility of complement measurement in 
pregnancy is unclear. However, the combination of low complement levels and high-activity 
lupus leads to a 3-5-fold increase in pregnancy loss and preterm birth [Clowse, 2004].  
AITT uses the macrophage cell line (IT-1) as a substrate that is wider than the ANA test 
in clinical applications   
The anti- dsDNA titer is very sensitive for the diagnosis of lupus and can be indicative of 
increased lupus activity, especially if the kidney is involved [Ho A, 2001]. Increased dsDNA 
which is considered for diagnosis and increased activity of the disease can be seen in 43% of 
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pregnant lupus women without disease activity, but rising titers of dsDNA is suggestive of 
increased lupus activity [Table 4]. However, this antibody does not predict pregnancy 
outcomes. Instead, the combination of a positive anti-dsDNA titer and highly active SLE 
contribute toward a 4-6-fold increase in perinatal mortality and a 2-3-folds decrease in full-
term birth [Clowse, 2004].  
 
                     Criteria         For  Lupus  Flare  
SYSTEM 
 
“VALID” “INVALID” 
Cutaneous Inflammatory rash Cloasma or  
Palmar erythema , 
Post partum alopecia 
Musculoskeletal Inflammatory arthritis Arthralgias 
Bland effusion 
Hematological  New leucopenia 
New Thrombocytopenia  
(PLT <80,000) 
Mild anemia 
ESR up to 40 mm 
Serological  Rising titer  
anti-dsDNA 
 
   
Constitutional  Fever not due to infection Fatigue 
   
Pulmonary Pain on inspiration Mild SOB, 
Hyperventilation 2° to 
Progesterone 
Source: JP Buyon MD  Rheumatologia  2(4) 199  (2004) 
Table 4. Criteria for lupus flare 
LE cell phenomenon is seen in lupus patient's blood. LE cell test was the first autoimmune 
disease test of using this phenomenon that showed lower sensitivity and specificity. So 
HEp-2 cell using the conventional antinuclear antibody (ANA) test is currently being used 
as a standard test. However AITT uses the macrophage cell line (IT-1) as a substrate that is 
wider than the ANA test in clinical applications. 
The ESR is unreliable in pregnancy because it increases significantly in normal pregnancy 
but if it is very high (>40mm/hr) it can be taken for increased lupus activity. In non-
pregnant SLE patients, CRP may increase with a lupus flare. The use of CRP has not been 
systematically tested in SLE pregnancies [Ho A, 2001]. As CRP is not elevated in pregnancy, 
it is to be considered for increased activity of the disease. Therefore elevated CRP is a better 
indicator for increased lupus activity than elevated ESR [Ruiz, 2004; Megan, 2007]. 
In a study (Table 5), complement C3 levels were statistically significant in hematuria, 
leucopenia, hypertension, high serum CRP levels, and preterm premature rupture of 
membranes. Complement C4 levels were statistically significant in kidney disease status, 
hematologic diseases and admissions to NICU. Anti-dsDNA was statistically significant in 
oligohydramnios, elevated CRP and neonatal anti-SSB (La) antibody detection. It is helpful 
to predict neonatal diseases.  AITT is statistically significant in high ESR values and Apgar 
score. This helps to predict state of the newborn immediately after birth [II Dong Kim, 2011]. 
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Complement C3 Complement C4 Anti-dsDNA AITT 
Leucopenia Hematological disease Anti-SSB/La 
antibodies 
(in neonates) 
 
Elevated CRP  Elevated CRP Elevated ESR 
Hypertension Proteinuria   
Hematuria Hematuria   
Premature rupture 
of Membranes  (PRM) 
Admission to NICU Oligohydramnios 1 & 5 minute 
Apgar score 
AITT=  Auto-immune Target Testing   
Table 5. Correlation of pregnancy complications with C3, C4, Anti-dsDNA and AITT  
Source: II Dong Kim et al. Korean J Obstet Gynecol 2011; 54:17-25 
In conclusion, although it is difficult to differentiate lupus activity from changes that occur 
in pregnancy, one needs to consider carefully all the above factors in a lupus pregnancy 
with high clinical suspicion of active disease for the diagnosis of increased lupus activity. 
4. Influence of pregnancy on SLE 
SLE patients suffer from different kinds of pregnancy related complications more than non-
SLE women. The following are the common pregnancy related complications. 
4.1 Hypertension 
Blood pressure levels tend to drop during pregnancy starting from the first trimester and 
increases at term.  Hypertension complicates 5% to 7% of all pregnancies. About 25% of 
lupus patients will develop hypertension and proteinuria in the second-half of pregnancy.  
In case of prior nephropathy of any type, hypertension develops in 41% of patients during 
pregnancy [How, 1985]. Pre-existing hypertension is the most common predisposing factor 
for preeclampsia. 
The risk of preterm birth, IUGR, and fetal loss, all increase in hypertensive pregnant lupus 
patients. Yasmeen, et al identified 555 deliveries in women with SLE and compared those 
pregnancy outcomes with outcomes in control group of 600,000 deliveries in women 
without SLE. The results showed that women with SLE had higher rates of adverse 
outcomes of pregnancy, including hypertensive complications, preterm delivery, cesarean 
delivery, IUGR, and fetal deaths, than did women without SLE.  The rate of hypertensive 
disorders of pregnancy were found to be 2.9% as compared to the controlled population 
which is only 0.4% [Yasmeen, 2001]. Hypertension can present in pregnancy as 
 Pregnancy-induced hypertension or gestational hypertension (blood pressure > 
140/90mmHg seen first time during pregnancy, returns to normal levels 12 weeks post 
partum)  
 Chronic hypertension (blood pressure > 140/90mmHg before pregnancy or diagnosed 
before 20 weeks of gestation or hypertension first diagnosed after 20 weeks of gestation 
and persistent after 12 weeks post partum) 
 Preeclampsia (blood pressure > 140/90mmHg after 20 weeks of gestation with  
proteinuria of  > 300mg/24hrs) 
 Eclampsia (preeclampsia with seizures) 
www.intechopen.com
 
Systemic Lupus Erythematosus 468 
4.2 Lupus flares 
There is conflicting data on whether SLE activity increases during pregnancy.  The risk of 
lupus flare is increased if the woman has had active lupus in the last 6 months of pregnancy. 
Therefore, inactive disease at the onset of pregnancy provides optimum protection against 
the occurrence of flare during pregnancy [Urowitz, 1993]. 
Lupus may flare during any trimester of pregnancy or post partum period.  The flares are 
usually mild mainly involving the joints, skin and blood. Some of the physiological changes 
of pregnancy can mimic the symptoms of the active disease such as palmar erythema, 
arthralgia, myalgia and lower limb edema [Table 4]. 
High prolactin levels, presence of lupus anticoagulant and increased SLE activity, have poor 
outcome in pregnancy [Jara, 2007a]. Oral Bromocriptine may play a role in the prevention of 
maternal-fetal complication such as premature rupture of membrane, preterm birth and 
active disease as reported in one of the clinical trials but this needs to be confirmed by 
further trials [Jara, 2007b]. 
The most important laboratory data to differentiate lupus flare in pregnancy from 
pregnancy changes include rising titer of anti-double strand DNA antibodies, presence of 
red blood cell casts in the urine, positive direct Coomb’s test and presence of antiplatelet 
antibody with thrombocytopenia. Complement levels can be in normal range as 
complement levels increases during pregnancy due to estrogen-induced hepatic synthesis of 
complements. 
In normal pregnancy the increased glomular filtration rate observed in the second 
trimester leads to increase in proteinuria.  Thrombocytopenia is seen in pregnancy, 
although it is generally mild and occurs only in 8% of women [Burrow, 1988].  The lupus 
activity index in pregnancy (LAI-P) scale which is a modified activity scale specific for 
pregnancy, studied by Ruiz-Irastorza G, et al showed ( LAI-P) high sensitivity to changes 
in lupus activity, and has a significant correlation with modified physician global 
assessment (M-PGA). This index has high sensitivity, specificity, predictive values, and 
likelihood ratios for diagnosing SLE flares during pregnancy and puerpurium [Riuz, 
2004].  
4.3 Preeclampsia 
SLE in general and hypertension and/or renal disease in particular were agreed upon by 
most studies to increase the risk for preeclampsia [Clowse, 2007].  Patients with class III and 
IV SLE nephritis have a significantly higher prevalence of preeclampsia (28% to 38%) as 
compared to class II or I (11.1%) or to lupus controls without nephritis (4.6%). 
It is important to differentiate isolated preeclampsia from lupus nephritis during pregnancy, 
as the corner stone in preeclampsia management is delivery of the fetus.  Preeclampsia as 
we mentioned previously is blood pressure levels of over 140/90 along with proteinuria of > 
300mg per 24 hour after 20 weeks gestation [Table 6].  Sometimes it can be associated with 
features of HELLP syndrome. If preeclampsia presents very early (< 20 weeks) one should 
look for the presence of APS (Antiphospholipid antibody syndrome).  Very severe cases of 
PET may evolve into eclampsia. 
In patients with no previous history of renal involvement and with normal baseline urinary 
parameters, preeclampsia is strongly supported by the onset of proteinuria in the third 
trimester, new onset hypertension, inactive urinary sediment, absence of anti-DNA 
antibodies and normal complements levels. 
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PARAMETER ACTIVE LUPUS NEPHRITIS PREECLAMPSIA 
High BP 
Proteinuria  
 
 
 
 
Edema  
Active Sediment 
Uric Acid 
C3, C4 
Anti-ds DNA Abs 
Present or Absent 
 >500 mg/24 hr if normal at 
baseline 
 Doubling if >500 mg/24 hr at 
baseline 
 Occur before 3rd trimester 
Present / Absent 
Present / Absent 
Normal or Elevated 
Low 
Rising 
Diastolic BP > 90 mm Hg 
 >300 mg/24 hr if 
normal at baseline 
 
 Occur during  
3rd trimester 
Present / Absent 
Absent 
Elevated 
Normal 
Absent  
Table 6. Broad Guidelines to differentiate Lupus Nephrites from Preeclampsia (Buyon, 2004) 
Antiplatelet agents during pregnancy, particularly the use of low dose Aspirin as primary 
prevention in PET are associated with moderate but consistent reduction in the relative risk 
of premature birth before 34 weeks gestation, and of having a pregnancy without serious 
adverse outcome [Askie, 2007].  A systemic review showed that Aspirin reduces the risk of 
perinatal death and preeclampsia in women with a history of risk factors such as 
preeclampsia, chronic hypertension, diabetes, and renal disease.  Given the importance of 
these outcomes and the safety along with low cost of aspirin, low dose aspirin should be 
considered in all women with the above risk factors [Coomarasamy, 2003].  Previous studies 
have suggested that several factors, including pre-existing hypertension, renal insufficiency, 
presence of APS, and active SLE, may increase the risk of preeclampsia in pregnancies 
complicated by SLE [Mascola, 1997]. The features which differentiate preeclampsia from 
lupus nephritis are given in Table 6. 
4.4 Lupus Nephritis (LN) 
Pregnant women with long-standing LN are at risk of spontaneous abortions and increased 
perinatal mortality.  However, the outlook of pregnancy in patients with stable LN at 
conception is relatively favourable. Remission in lupus nephritis has been defined as stable 
renal function, a serum creatinine within the normal range, urinary red cells below 5/high 
power field, proteinuria below 0.5g/day and normal serum C3 levels for the last 12-18 
months (Table 6) [Gayed, 2007].   
The incidence of obstetric complications and maternal mortality is high in patients with 
active lupus nephropathy associated with pre-existing hypertension.  Pregnant women with 
LN require intense fetal and maternal surveillance for a better outcome of pregnancy 
[Rahman, 2005]. The increase in proteinuria can be secondary to the usual increase in 
glomerular filtration rate observed in the second trimester of pregnancy. Moderate renal 
impairment at the onset of pregnancy, as reflected by serum creatinine level of 120µmoles/L 
or greater, has a greater decline in renal function than would be expected in a non-pregnant 
patient for a similar time period [Hou, 1985]. 
The fetal loss in patients with active LN in pregnancy occurs in 36% to 52% of the 
pregnancies, as compared to fetal loss in pregnant patients with history of LN but with 
stable creatinine and minimal proteinuria during pregnancy, which is only 11% to 13% 
[Huong, 2001; Moroni, 2002].  A study of 24 pregnancies in 22 women with LN noticed 
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flares in 50% with proteinuria, 42% with hypertension, and 25% with preeclampsia 
[Soubassi, 2004].  Lupus nephritis flare can be associated with other evidence of active lupus 
such as serositis, arthritis, and high titers of anti-DNA antibodies. The proteinuria of 
preeclampsia decreases after delivery but not that of active lupus patient. 
4.5 Thrombocytopenia  
It is not unusual to see this in pregnancy. It is encountered in at least 8% of all pregnancies.  
In gestational thrombocytopenia, the degree of thrombocytopenia is usually mild, with no 
history of bleeding or preconception history of thrombocytopenia. The platelet count 
usually returns to normal within 2-12 weeks post partum [Jeffrey, 2002].  Also, 
thrombocytopenia may occur for a variety of reasons in pregnancy such as SLE, APS, 
HELLP or medication particularly Heparin or expanding of circulatory volume.  
4.6 Other complications   
Pregnant lupus patients can face other problems like HELLP syndrome (Hemolysis Elevated 
Liver enzymes and Low Platelets) and Gestational diabetes [Joya, 2010, Josephine, 2006]. 
5. Influence of SLE on pregnancy  
5.1 Effect on fertility 
Systemic lupus erythematosus (SLE) is not known to affect the fertility directly and 
therefore SLE patients are as fertile as any other female in general population [Kamashta, 
1996]. Lowered fertility rate is seen in patients with active disease on high dose steroids, 
patients with established renal disease and moderate to severe renal failure [Hou, 1975].  
End-stage renal disease secondary to lupus nephritis can result in amenorrhea, although 
amenorrhea in renal patients may also be due to ovarian failure secondary to 
cyclophosphamide or of auto-immune origin [Kong, 2006]. 
5.2 Effect of flare on conception 
SLE patients can experience disease flare at anytime during pregnancy with potential 
negative effects on the conception.  Lupus flares occur more during pregnancy and post 
partum period in SLE patients than non-SLE pregnant patients [Petri, 1991].  Increased 
lupus activity is seen after pregnancy in 1/3 of cases [Seng, 2008]. Therefore, for better 
outcome of lupus pregnancy it is essential to control disease activity and achieve clinical 
remission at least 6 months before pregnancy [Georgion, 2000]. 
Exacerbations or relapses occur during the course of pregnancy and immediate post partum 
period in 25% to 60% of cases.  However, the likelihood of increased clinical activity of SLE 
during pregnancy is influenced by signs of activity present at onset of pregnancy.  In the 
absence of signs of clinical activity for at least 6 months before conception, relapses occur 
only in one-third of cases, whereas in patients with clinical activity at onset of pregnancy, 
persistent activity or exacerbations occur in approximately two-thirds. 
Fetal survival in these patients parallels with the incidence of SLE activity: Hence fetal 
survival is seen in 85% to 95% in the group with inactive disease at conception and 50% to 
80% in subjects with active disease at the onset of pregnancy [Weyslett, 1991]. More recent 
studies have shown a 2-3 fold increase in SLE activity during pregnancy [Rehman, 2005]. 
Adverse live-birth outcome was significantly associated with low pre-gestational serum 
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albumin level, elevated gestational anti-ds DNA antibody, and diabetes mellitus.  
Spontaneous abortion was directly associated with low levels of pre-gestational serum 
albumin, positive anticardiolipin IgA, anti-B2-glycoprotein IgM, and anti-La antibodies. 
 
Complication 
Moderate to severely 
active SLE (n=57) 
Inactive or mildly 
active SLE (n=210) 
P-
value 
Miscarriage 7% 7% 0.9 
Stillbirth: 16% 5% <0.01 
Extreme Preterm (<28 weeks 
gestation) 
17% 6% 0.09 
Late Preterm (28 to 37 weeks 
gestation) 
49% 26% <0.001 
Small for gestational age baby (<10th 
percentile weight for gestational age) 
30% 21% 0.23 
Table 7. Increased Lupus Activity in Pregnancy Increases Pregnancy Complications 
(Data from Clowse MEB et al. The impact of increased lupus activity on obstetric outcomes. 
Arthritis Rheum, 2005. 52(2): p. 514–21) 
5.3 Effect of lupus nephritis  
The obstetric complications and maternal mortality is high in patients with active lupus 
nephropathy associated with pre-existing hypertension [Rahman, 2005]. Pregnant women 
with long-standing lupus nephritis are at high risk of spontaneous abortions and increased 
perinatal mortality. However, the outlook of pregnancy in patients with stable lupus 
nephritis at conception is relatively favorable [Table 7]. Patients with the combination of 
either high clinical activity of SLE and low complement or positive anti-ds DNA had the 
highest rate of pregnancy loss and preterm birth [Clowse, 2011]. 
Female recipients transplanted for renal failure secondary to lupus nephritis can maintain 
pregnancy successfully. Outcomes are comparable to renal recipients with other diagnoses.  
Newborns in both groups were often premature and had low birth weight [McGrory, 2003].  
The second trimester Doppler ultrasound examination is the best predictor of late 
pregnancy outcome in systemic lupus erythematosus and/or the anti-phospholipids 
syndrome [Lethi, 2006]. 
Management of pregnant women with renal disease involves awareness of physiological 
changes such as decreased serum creatinine and increased proteinuria. Worsening 
proteinuria may be due to lupus flare but differential diagnosis also includes preeclampsia.  
In fact, women with severe renal impairment (serum creatinine over 300µmols/L) have a 
chance lower than 30% of having successful pregnancy [Germin, 2006]. 
5.4 Effect of Antiphospholipid Syndrome (APS) 
Anti-phospholipids antibodies (APL), which include lupus anti-coagulant (LAC),  
anti-cardiolipin antibodies (ACL), and B2glycoprotein are frequently found in patients with 
SLE, and their presence has been associated with increased fetal loss. If APL are present,  
the fetuses are susceptible to placental insufficiency. APL but not anti-Ro and anti-La  
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Term Definition 
Spontaneous abortions or miscarriages Pregnancy loss <20 weeks of gestation 
Recurrent abortion  or recurrent 
miscarriages 
≥3 spontaneous abortions 
Fetal loss Pregnancy loss from 10 weeks of gestation and 
onwards 
Intrauterine fetal demise (IUFD) or 
stillbirth 
Fetal death occurring at ≥20 weeks of gestation 
Fetal wastage Sum of spontaneous abortions and stillbirths 
Neonatal death Infant born live but died up to 28 days after birth 
Small for gestational age Birth weight <10th percentile 
Low birth weight Birth weight <2500 g 
Very low birth weight Birth weight <1500 g 
Preterm birth or prematurity Gestational age <37 weeks 
Table 8. Adverse pregnancy outcomes  
(Data from Josephine P et al-Lupus and pregnancy: complex yet manageable  
Clin Med Res 2006 Dec; 4(4):310-321) 
antibodies might have a role in direct placental damage. The levels of ǃ-hCG are reduced in 
women with history of recurrent pregnancy loss or thromboembolic  events. High titers of 
APL were found to cause the largest reduction in ǃ-hCG. Anti-Ro and anti-La did not 
induce placental damage [Schwartz, 2007]. APL also have direct effect on trophoblast 
possibly through exposed anionic phospholipids and/ or adherent B2glycoprotein “B2GP1”, 
resulting in altered trophoblast intercellular fusion, gonadotropin secretion and trophoblast 
invasiveness [Di Simone, 2005]. 
Typical fetal loss secondary to APS is characterized by progressive intrauterine growth 
restriction (IUGR) ultimately leading to fetal death [Birdsall, 1996].  Both early and late fetal 
deaths are associated with APS [Rai, 1995].  The live birth of an APS pregnancy rate 
increased from 19% in untreated patients to 70% in treated patients [Lima, 1996].  The risk of 
pregnancy loss in women with anti-phospholipids antibodies (APL) and with a previous 
pregnancy loss has been estimated at over 60%. APS pregnancy is not without complications 
in the mother [Table 9]. 
Beside those already mentioned, pregnancy confers a higher risk of thrombosis in women 
who are already at increased risk or with a past history of thrombotic events [Branch, 1992]. 
The incidence of extensive infarction, decidual vasculopathy, decidual thrombosis and 
perivillous fibrinoid change, which have been thought to be characteristic lesions of APS 
placenta, was significantly higher in LAC, or ACL or both LAC & ACL positive patients 
than in the patients without APL.  LAC and ACL double-positivity is an important risk 
factor for fetal death in the SLE patient [Petri, 2004; Ogishima, 2000]. 
As the placenta positive for IgG-APL showed pathogenic findings such as infarction, 
degeneration, thrombus formation and fibrinoid deposits, it is suggested that IgG-APL 
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bound to the placental tissue might cause direct pathologic damage to the placenta which 
results in IUFD, or IUGR by uteroplacental insufficiency [Katoro, 1995]. 
 
Fetal Risks Maternal Risks 
 Recurrent miscarriage (first and 
second trimester) 
 Thrombosis 
 Intrauterine growth restriction  Severe early onset preeclampsia 
 Fetal death   Preterm labour, rupture of membranes 
 Premature delivery  Worsening of pre-existing 
thrombocytopenia 
 Congenital malformations/ 
intracerebral haemorrhage  
(If Warfarin is administered) 
 Placental abruption 
 Other bleeding complications 
Table 9. Obstetric risks associated with anti-phospholipid syndrome 
(Adapted from S Stone, MA Khamashta, and L Poston [Stone, 2001]) 
Fetal risk had been reduced progressively in the past 40 years.  Although it still continues to 
be higher than that occurring in pregnancies of healthy women. The presence of APL 
considerably worsens the fetal outcome [Moroni, 2005]. It is suggested that patients with 
early-onset severe preeclampsia be screened for APL, if antibodies are detected, then these 
women should be considered for prophylactic anticoagulation therapy [Branch, 1989]. 
A retrospective case-control study of 242 pregnancies in 112 patients concluded that the risk 
of fetal loss in SLE is 2.5 times higher than that in the normal population.  The presence of 
LAC indicated a high risk of fetal loss, while the absence of APL is an indication of a 
favorable pregnancy outcome.  No individual APL test seems to be clearly superior to the 
others to detect patients at high risk for fetal loss.  However, by combining ACL with LAC, a 
reasonably good sensitivity and specificity can be achieved.  Regardless of APL, infants of 
women with SLE are born more prematurely and are more retarded in growth than the 
infants in the normal population.  Thus, factors other than APL also contribute to the 
adverse fetal outcome in lupus pregnancy [Heikki, 1993]. 
5.5 Effect of anti-ro/and or anti-la antibodies 
SLE is the most recognized Rheumatic disease in which auto antibodies, anti-Ro and/or 
anti-La can pass from the mother to the fetus across the placenta during pregnancy. Anti-
Ro/SSA antibodies are associated with neonatal lupus but do not negatively affect other 
gestational outcomes, and the general outcome of these pregnancies is now good.  A large 
multi-centers cohort prospective controlled study of 100 anti-Ro/SSA positive women 
concluded that anti-Ro/SSA antibodies are responsible for congenital heart block but do not  
affect other outcomes of pregnancy, both in SLE and non-SLE women.   
The general outcome for these pregnancies is now very good, if prospectively followed by 
multidisciplinary teams [Antonio, 2011; Brucato, 2002], although various studies considered 
the anti-Ro/SSA antibody as a possible causative factor for unexplained pregnancy loss.  A 
significant greater fetal wastage is seen in black anti-Ro (SSA) positive women as compared 
to black anti-RNP positive women.  No significant difference in fetal wastage was noted 
between the white SLE and the non-SLE women in either antibody group. These data 
suggest that black SLE patients with anti-Ro (SSA) antibody may be at increased risk of fetal 
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wastage [Watson, 1986].  Hull et al reported three SLE patients with anti-Ro/SSA and a 
history of spontaneous abortions [Hull, 1983]. 
Ro52, Ro60 and La IgG antibodies all are transferred from the mothers to their fetus in utero 
and were present in the infant at birth as detected by enzyme-linked immunosorbent assay 
using recombinant antigens and a synthetic peptide.  A significant decrease in Ro52, Ro60 
and LA IgG auto antibody levels the infants was observed from birth to 4-5 weeks of the 
age. Ro- and La-specific IgA and IgM antibodies were detected in the serum from a subset of 
mothers.  However, Ro- and La-specific IgA and IgM antibody levels were low or non-
detectable in children raised both with and without breastfeeding.  These findings support a 
role for placental materno-fetal transfer of the IgG auto antibodies in the pathogenesis of 
neonatal lupus erythematosus (NLE) and indicate that refraining from breast-feeding does 
not protect from NLE skin involvement [Klauinger, 2009]. 
Studies focusing on the neuropsychological development of SLE offspring show an 
increased number of learning disabilities in children with normal intelligence levels.  The 
presence of anti-Ro/La antibodies and disease activity (flare) in mothers during pregnancy 
were significantly related to higher prevalence of learning disabilities in offspring.  Mainly 
sons of women with SLE were significantly more likely to have learning disabilities than 
daughters of women with SLE or children of either sex in the control group as these 
maternal antibodies likely affect the fetal brain of male offspring and result in later learning 
problems.  These findings should promote greater awareness and early educational 
intervention in those children [Ross, 2003].  
5.6 Other risks  
Prospective studies indicate that the majority of lupus mothers can sustain pregnancy 
without detrimental effects, provided that the pregnancy is planned during the inactive 
phase of the disease.  Nevertheless the fetal risk, although progressively reduced during the 
last 40 years, continues to be higher, particularly in patients with anti-phospholipids 
antibodies (APL), than in pregnancies in healthy women [Moroni, 2003]. 
Premature rupture of membranes (PROM) is more common in pregnancies occurring in 
women with SLE which is the major etiology for preterm births [Johnson, 1995]. SLE is 
associated with increased risk of spontaneous abortion (pregnancy loss prior to 20 weeks 
gestation), preeclampsia, stillbirth (pregnancy loss after 20 weeks gestation), premature 
rupture of membrane (PROM), intrauterine growth restriction and fetal death. 
The risk of thrombosis, infection, thrombocytopenia and requirement for transfusions is 
higher in women with SLE.  Lupus patients also have a higher risk for cesarean sections, 
preeclampsia, and are also more likely to have other medical conditions like diabetes, 
hypertension, and thrombophilia which are also associated with adverse pregnancy 
[Clowse, 2008]. 
SLE women belong to category of high-risk pregnancy.  Highly active lupus during 
pregnancy leads to increased premature birth and a decrease in live births, with almost one-
quarter of these pregnancies resulting in fetal loss.  The Hopkins Lupus Center Database has 
identified a combination of two factors: high clinical activity and serologic activity. These 
two are very important factors which predict preterm birth.  Pregnancies in lupus patients 
must be closely watched and treated during all the three trimesters to improve pregnancy 
outcomes [Urowitz,1993; Chandran, 2005]. 
www.intechopen.com
 
SLE and Pregnancy 475 
6. Conclusion  
SLE is a chronic multisystem disease occurring in young women in their childbearing  
age. And therefore, the collaboration of rheumatologist and obstetrician who are 
experienced in high risk pregnancies management, are essential for managing these 
women with lupus who becomes pregnant to have a successful outcome as these women 
already have high risk in terms of fetal loss and spontaneous abortions [Georgion, 2000]. 
The manifestations of normal pregnancy can be mistaken as signs of lupus activity 
making the diagnosis and treatment challenging. Therefore, understanding of pregnancy 
and lupus interaction has resulted in better methods of monitoring and treating this 
particular clinical situation. 
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